Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API

Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing
        Collaboration With Mitsubishi Healthcare Unit API Corporation

--APIC Investment in Neuland's Facilities Will Allow Neuland to Produce
Competitively-Priced Pharmaceutical Products for APIC--

PR Newswire

HYDERABAD, India, March 12, 2013

HYDERABAD, India, March 12, 2013 /PRNewswire/ -- Neuland Laboratories Ltd.,
(NSE:NEULANDLAB; BOM:524558) a pharmaceutical manufacturer providing active
pharmaceutical ingredients (APIs), complex intermediates and contract
manufacturing services to customers located in 85 countries, today announced a
manufacturing collaboration with Tokyo-based API Corporation (APIC), a
healthcare unit of Mitsubishi Chemical Holdings Group that produces APIs,
intermediates and investigational new drugs, along with fine chemicals and
reagents.

Under the terms of the agreement, API Corporation is making an investment in
Neuland's facilities that will provide APIC with dedicated capacity for
meeting the needs of its customers.The facilities will be operated by Neuland
employees and the two companies will share oversight and management
responsibilities.

"We are impressed with Neuland's long history of quality production and
regulatory excellence. In addition, their business model of being solely
focused on API and intermediates manufacture makes them an ideal partner for
APIC," said Taiichi Emura, President of APIC.

"This agreement between Neuland and APIC is an outstanding example of a
win-win collaboration between companies that share many values and are
complementary in terms of capabilities and markets served," said Dr. D.R. Rao,
Chairman and Managing Director of Neuland Labs Ltd. "We have recently been
strengthening our presence in the Japanese market, while APIC was seeking an
Indian partner to better serve customers. This alliance will allow us to
raise our profile in Japan while enabling our partner APIC to grow their
business in a cost-effective way."

Neuland also intends to continue to independently expand its already-sizeable
business in Japan, building on its significant customer base for both generic
API manufacturing and contract manufacturing of APIs and intermediates.

Dr. Rao added, "Our work with APIC has already been valuable in increasing our
understanding of the unique requirements of the Japanese market. We are
confident that we have adequate production capacity to serve both existing and
new customers and believe that this collaboration will further enhance our
ability to serve all of our customers around the globe."

Neuland Laboratories is listed on India's National Stock Exchange under the
symbol NEULANDLAB and on the Bombay Stock Exchange under code 524558 and the
symbol Neuland.EO.

About Neuland Labs
For over 25 years Neuland Labs has been at the forefront of manufacturing APIs
through its cGMP manufacturing facilities, working with customers in 85
countries. Neuland Labs has developed more than 300 processes and 60 APIs,
and it has filed more than 40 US drug master files (DMFs), 10 EU CEPs and a
total of more than 400 DMFs worldwide. Its manufacturing facilities are
inspected and approved by the US FDA and other leading regulatory agencies.
Its recod of quality manufacturing and reliability is highlighted by cGMP
certifications that include the FDA, TGA, EDQM, German Health Authority, ISO
14001, ISO 27001 and OHSAS 18001. For more information, visit
www.NeulandLabs.com.

Contacts:                     US Media
Neuland Laboratories Ltd.
NS Viswanathan                BLL Partners/Brandwidth Solutions
Chief Financial Officer       Barbara Lindheim
+91 40 30211600               +1 212 584-2276
nsviswanathan@neulandlabs.com blindheim@bllbiopartners.com

SOURCE Neuland Laboratories Ltd.

Website: http://www.NeulandLabs.com
 
Press spacebar to pause and continue. Press esc to stop.